// App-Quantinova.ai

2972 : Co-clinical trial of olaparib and temozolomide in SCLC PDX models uncovers new biomarkers of sensitivity

Researchers

Presenter

  • Benjamin J. Drapkin

Principal Investigators

  • Marcello Stanzione

  • Beow Y. Yeap

  • Mari Mino-Kenudson

  • Camilla L. Christensen

  • Ruben Dries

  • Sarah Phat

  • Jun Zhong

  • David T. Myers

  • Joseph A. Licausi

  • Tilak Sundaresan

  • Marina Kem

  • Nima Abedpour

  • Leica V. Sequist

  • Alice T. Shaw

  • Aaron N. Hata

  • Mehmet Toner

  • Shyamala Maheswaran

  • Daniel A. Haber

  • Martin Peifer

  • Roman K. Thomas

  • Anna F. Farago

  • Nicholas J. Dyson

Medical Centers

  • Massachusetts General Hospital, Boston, MA

  • University of Cologne, Cologne, DE, Germany

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Temozolomide

  • Olaparib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved